AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8739008 — intervention group
Group type: EXPERIMENTAL
Intervention: Full implementation of the protocol
Number of subjects: 104
Study 8739008 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc-defined patient categories (cases with hernia, chronic and nonchronic cases)
Number of subjects: 104
Study 2008865 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100-150 mg/d)
Number of subjects: 55
Study 2008865 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 55
Study 2008865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6807439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 600 mg/m2 daily for three days
Number of subjects: 22
Study 6807439 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone 3 mg/kg daily for three days
Number of subjects: 22
Study 6807439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 22
Study 6807439 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 22
Study 31974279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty (VP)
Number of subjects: 0
Study 31974279 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30608050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-plus-behavior-change (handwashing promotion and drinking water chlorination)
Number of subjects: 60000
Study 30608050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera-vaccine-only
Number of subjects: 60000
Study 30608050 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60000
Study 30608050 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of soap and water in handwashing station
Number of subjects: 60000
Study 29438123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry eye group (n=46)
Number of subjects: 112
Study 29438123 — intervention group
Group type: COMPARATOR
Intervention: Non-dry eye group (n=66)
Number of subjects: 112
Study 29438123 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 112
Study 29438123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry eye group subjects
Number of subjects: 112
Study 29438123 — intervention group
Group type: COMPARATOR
Intervention: Non-dry eye group subjects
Number of subjects: 112
Study 26886418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (target dose, 45 mg daily)
Number of subjects: 3876
Study 26886418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876
Study 26886418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3876
Study 25223743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) ON
Number of subjects: 20
Study 25223743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SNS OFF)
Number of subjects: 20
Study 22148897 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 1 g/day
Number of subjects: 1600
Study 22148897 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 1600
Study 22148897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1600
Study 22148897 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (1 or 2 g/day)
Number of subjects: 1600
Study 20806323 — intervention group
Group type: EXPERIMENTAL
Intervention: Developing motor control; participants reported target presence or absence by pressing a key or marking on recording sheets.
Number of subjects: 0
Study 17947609 — intervention group
Group type: EXPERIMENTAL
Intervention: AA/DHA supplementation (10 gel caps containing 500 mg of AA and 1000 mg of DHA daily for 6 weeks)
Number of subjects: 9
Study 17947609 — intervention group
Group type: COMPARATOR
Intervention: OA/LA supplementation (250 mg of linolenic acid and 125 mg of oleic acid daily for 6 weeks)
Number of subjects: 9
Study 15617993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) + Vinorelbine (VNR) 25 mg/m(2) on days 1 and 8 as an intravenous bolus plus CP 75 mg/m(2) on day 1 (regimen A)
Number of subjects: 272
Study 15617993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) + Gemcitabine (GEM) 1200 mg/m(2) on days 1 and 8 as an intravenous 30-min infusion plus CP 75 mg/m(2) on day 1 (regimen B)
Number of subjects: 272
Study 12384827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (100 microg/h)
Number of subjects: 24
Study 12384827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10414012 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) program
Number of subjects: 0
Study 10414012 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) program with comprehensive case management services
Number of subjects: 0
Study 10414012 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) program with more intensive services
Number of subjects: 0
Study 10414012 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (part of the PAT program)
Number of subjects: 0
Study 10414012 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for primarily Spanish-speaking Latino families
Number of subjects: 0
Study 7798688 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP polysaccharide vaccine
Number of subjects: 50
Study 7798688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate PRP-D vaccine
Number of subjects: 50
Study 7798688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate HbOC vaccine
Number of subjects: 50
Study 7798688 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (unimmunized)
Number of subjects: 50
Study 7798688 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccines
Number of subjects: 50
Study 7798688 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP IgG1 subclass
Number of subjects: 50
Study 7798688 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunized mothers
Number of subjects: 50
Study 7798688 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP conjugate vaccines
Number of subjects: 50
Study 2186591 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 36
Study 2186591 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 36
Study 29383649 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Children's Anxiety and Depression Scale (RCADS)
Number of subjects: 126
Study 29383649 — intervention group
Group type: COMPARATOR
Intervention: Network analysis of RCADS anxiety items
Number of subjects: 126
Study 30396622 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga as an adjunct therapy
Number of subjects: 0
Study 27550184 — intervention group
Group type: EXPERIMENTAL
Intervention: Gongjin-dan (GJD) administered twice daily
Number of subjects: 24
Study 27550184 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily
Number of subjects: 24
Study 24508316 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual mobilization of the wrist (10 minutes, integrated into therapy twice a week for 6 weeks)
Number of subjects: 18
Study 24508316 — intervention group
Group type: COMPARATOR
Intervention: Control group (therapy based on Dutch guidelines for stroke without manual mobilization)
Number of subjects: 18
Study 22975763 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon + ribavirin + boceprevir (PRB)
Number of subjects: 0
Study 22975763 — intervention group
Group type: COMPARATOR
Intervention: peginterferon + ribavirin (PR)
Number of subjects: 0
Study 22975763 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 20429912 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreatic head resection
Number of subjects: 100
Study 20429912 — intervention group
Group type: COMPARATOR
Intervention: Pancreatoduodenectomy
Number of subjects: 100
Study 17170051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg BIIL 284
Number of subjects: 342
Study 17170051 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg BIIL 284
Number of subjects: 342
Study 17170051 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg BIIL 284
Number of subjects: 342
Study 17170051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 16314680 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 29
Study 16314680 — intervention group
Group type: COMPARATOR
Intervention: Control (no OMT)
Number of subjects: 29
Study 12452546 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 20
Study 12452546 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study 9794948 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant treatment (100 mg/kg body weight bovine surfactant)
Number of subjects: 317
Study 9794948 — intervention group
Group type: COMPARATOR
Intervention: Late surfactant treatment (100 mg/kg body weight bovine surfactant)
Number of subjects: 317
Study 9794948 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant treatment
Number of subjects: 317
Study 9794948 — intervention group
Group type: COMPARATOR
Intervention: Late surfactant treatment
Number of subjects: 317
Study 7708981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (A)
Number of subjects: 103
Study 7708981 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Alfentanil (M+A)
Number of subjects: 103
Study 7708981 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (M)
Number of subjects: 103
Study 2615932 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of L-tryptophan
Number of subjects: 20
Study 2615932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 208034 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinestrol 0.2 mg once weekly
Number of subjects: 156
Study 208034 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinestrol 0.1 mg once weekly
Number of subjects: 156
Study 208034 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 1.25 mg daily for 21 days on and 7 days off
Number of subjects: 156
Study 208034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 30601336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of tenofovir (TDF) and telbivudine (LdT)
Number of subjects: 121
Study 30601336 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir (TDF) single treatment
Number of subjects: 121
Study 27364375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium dialysate (1.3 mmol/L)
Number of subjects: 50
Study 27364375 — intervention group
Group type: COMPARATOR
Intervention: High calcium dialysate (1.6 or 1.75 mmol/L)
Number of subjects: 50
Study 27364375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LC and HC)
Number of subjects: 50
Study 26237308 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold Suspend (TS) feature
Number of subjects: 247
Study 26237308 — intervention group
Group type: COMPARATOR
Intervention: Control Group (sensor-augmented pump only)
Number of subjects: 247
Study 24004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground visual cue training (O-VCT)
Number of subjects: 60
Study 24004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill visual cue training (T-VCT)
Number of subjects: 60
Study 24004882 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60
Study 21352609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PQP)
Number of subjects: 304
Study 21352609 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 304
Study 17689755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (four drops of essential oil diluted with 20 ml of hot water and inhaled for 30 min)
Number of subjects: 30
Study 17689755 — intervention group
Group type: COMPARATOR
Intervention: Control (no aromatherapy)
Number of subjects: 30
Study 15651074 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard support group
Number of subjects: 181
Study 15651074 — intervention group
Group type: COMPARATOR
Intervention: Complementary/alternative (CAM) oriented intervention
Number of subjects: 181
Study 12497304 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetin (37 patients, dosage: 20-40 mg/day)
Number of subjects: 77
Study 12497304 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (40 patients, dosage: 25-75 mg/day)
Number of subjects: 77
Study 9845814 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated matrix pellets with enteric polymers (methacrylate copolymers, hydroxypropyl methylcellulose acetate succinates, cellulose acetate phthalate) as binders and coating material.
Number of subjects: 0
Study 9845814 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated pellets for furosemide.
Number of subjects: 0
Study 7540898 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (200 micrograms)
Number of subjects: 14
Study 7540898 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms)
Number of subjects: 14
Study 7540898 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 micrograms)
Number of subjects: 14
Study 1673953 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily (n = 54)
Number of subjects: 107
Study 1673953 — intervention group
Group type: COMPARATOR
Intervention: H2 receptor antagonist (n = 53)
Number of subjects: 107
Study 6269769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus prophylactic whole brain radiation therapy
Number of subjects: 30
Study 6269769 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 30
Study 28489629 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA; 0.057 mA·cm)
Number of subjects: 20
Study 28489629 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 26105140 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 31
Study 26105140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26376805 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg)
Number of subjects: 275
Study 26376805 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (200-300 mg)
Number of subjects: 275
Study 26376805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 24247554 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (leukine), 500 μg/day 3 times a week for 4 weeks
Number of subjects: 159
Study 24247554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 24247554 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 159
Study 21086125 — intervention group
Group type: EXPERIMENTAL
Intervention: Proctored training (automated simulator feedback plus human expert feedback)
Number of subjects: 32
Study 21086125 — intervention group
Group type: COMPARATOR
Intervention: Independent training (simulator feedback alone)
Number of subjects: 32
Study 21086125 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of the actual procedure
Number of subjects: 32
Study 21086125 — intervention group
Group type: COMPARATOR
Intervention: Watching the instructional video alone
Number of subjects: 32
Study 18412964 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of nurse specialists in primary care for urinary incontinence
Number of subjects: 350
Study 18412964 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 350
Study 17053841 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed clinical classification of tetanus patients (grades I to IV)
Number of subjects: 64
Study 15181047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LF)
Number of subjects: 31
Study 15181047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LC)
Number of subjects: 31
Study 15181047 — intervention group
Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 31
Study 11069440 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (once daily for 9 days)
Number of subjects: 20
Study 11069440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amlodipine
Number of subjects: 20
Study 11069440 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice coadministration
Number of subjects: 20
Study 11069440 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 20
Study 9296217 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 250 mg
Number of subjects: 152
Study 9296217 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 500 mg
Number of subjects: 152
Study 8507221 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin (2.5-5.0 mg orally, given 24 hours after weekly methotrexate dose)
Number of subjects: 92
Study 8507221 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given 24 hours after weekly methotrexate dose)
Number of subjects: 92
Study 8507221 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin
Number of subjects: 92
Study 8507221 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin and Placebo
Number of subjects: 92
Study 3551829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime monotherapy
Number of subjects: 102
Study 3551829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus cephalothin
Number of subjects: 102
Study 3551829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus vancomycin
Number of subjects: 102
Study 3551829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime and cephalothin plus vancomycin
Number of subjects: 102
Study 31813028 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 0
Study 31813028 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 28843819 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-based systemic antibiotics (oral rifampicin with clindamycin or trimethoprim/sulfamethoxazole for 7 days plus nasal mupirocin)
Number of subjects: 52
Study 28843819 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with mupirocin only
Number of subjects: 52
Study 27141840 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention (II)
Number of subjects: 94
Study 27141840 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 94
Study 25494594 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn peptides (CPs) 4 g/d for 9 weeks
Number of subjects: 161
Study 25494594 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (2 g twice daily)
Number of subjects: 161
Study 25494594 — intervention group
Group type: COMPARATOR
Intervention: Corn starch placebo (2 g twice daily)
Number of subjects: 161
Study 22430300 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (50 U BT into the internal sphincter)
Number of subjects: 50
Study 22430300 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 50
Study 20362857 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom PRK (wavefront-guided custom treatment)
Number of subjects: 28
Study 20362857 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 28
Study 18384186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 0
Study 18384186 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 15714983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade using LHRH agonist and androgen antagonist
Number of subjects: 0
Study 15714983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade
Number of subjects: 0
Study 15714983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy (including intermittent hormonal therapy)
Number of subjects: 0
Study 12879653 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with gonadotropins
Number of subjects: 172
Study 12879653 — intervention group
Group type: COMPARATOR
Intervention: Classic stimulation protocol alone
Number of subjects: 172
Study 12879653 — intervention group
Group type: COMPARATOR
Intervention: Intact ovarian function
Number of subjects: 172
Study 11051123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulthiame (STM) 5 mg/kg/day
Number of subjects: 66
Study 9006790 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (90 mg) and caraway oil (50 mg) in an enteric coated capsule
Number of subjects: 45
Study 9006790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1587072 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg extended-release fenfluramine plus 15 mg phentermine resin
Number of subjects: 121
Study 1587072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 3890395 — intervention group
Group type: EXPERIMENTAL
Intervention: Muzolimine (MZ) 20 mg/day
Number of subjects: 26
Study 3890395 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL) 50 mg/day
Number of subjects: 26
Study 3890395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study 3890395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MZ and CL
Number of subjects: 26
Study 29419569 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg every day
Number of subjects: 40
Study 26689970 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir Disoproxil Fumarate (FTC/TDF)
Number of subjects: 4
Study 26689970 — intervention group
Group type: COMPARATOR
Intervention: No detectable drug
Number of subjects: 4
Study 26689970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 26689970 — intervention group
Group type: COMPARATOR
Intervention: No FTC/TDF
Number of subjects: 4
Study 23321657 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vaginal estrogen cream for 2 to 12 weeks
Number of subjects: 42
Study 23321657 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 42
Study 21406117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound plus exercise therapy
Number of subjects: 46